PVLA
NASDAQ HealthcarePalvella Therapeutics, Inc. - Common Stock
Biotechnology
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
๐ Market Data
| Price | $147.77 |
|---|---|
| Volume | 268,788 |
| Market Cap | 2.12B |
| RSI (14-Day) | 57.3 |
| 200-Day MA | $105.40 |
| 50-Day MA | $124.52 |
| 52-Week High | $161.38 |
| 52-Week Low | $28.19 |
| Forward P/E | -21.67 |
| Price / Book | 9.10 |
๐ฏ Investment Strategy Scores
PVLA scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (54/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Moon Shot (6/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find PVLA in your text
Paste any article, transcript, or post โ the tool will extract PVLA and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.